vs

Side-by-side financial comparison of EXTREME NETWORKS INC (EXTR) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

EXTREME NETWORKS INC is the larger business by last-quarter revenue ($316.9M vs $207.3M, roughly 1.5× Ultragenyx Pharmaceutical Inc.). EXTREME NETWORKS INC runs the higher net margin — 3.3% vs -62.0%, a 65.4% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 11.4%). EXTREME NETWORKS INC produced more free cash flow last quarter ($7.8M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 11.1%).

Extreme Networks, Inc. is an American networking company based in Morrisville, North Carolina. Extreme Networks designs, develops, and manufactures wired and wireless network infrastructure equipment and develops the software for network management, policy, analytics, security and access controls.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

EXTR vs RARE — Head-to-Head

Bigger by revenue
EXTR
EXTR
1.5× larger
EXTR
$316.9M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+14.5% gap
RARE
25.9%
11.4%
EXTR
Higher net margin
EXTR
EXTR
65.4% more per $
EXTR
3.3%
-62.0%
RARE
More free cash flow
EXTR
EXTR
$108.6M more FCF
EXTR
$7.8M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
11.1%
EXTR

Income Statement — Q4 FY2026 vs Q4 FY2025

Metric
EXTR
EXTR
RARE
RARE
Revenue
$316.9M
$207.3M
Net Profit
$10.6M
$-128.6M
Gross Margin
61.7%
Operating Margin
5.5%
-54.7%
Net Margin
3.3%
-62.0%
Revenue YoY
11.4%
25.9%
Net Profit YoY
202.9%
3.5%
EPS (diluted)
$0.08
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXTR
EXTR
RARE
RARE
Q2 26
$316.9M
Q4 25
$317.9M
$207.3M
Q3 25
$310.2M
$159.9M
Q2 25
$307.0M
$166.5M
Q1 25
$284.5M
$139.3M
Q4 24
$279.4M
$164.6M
Q3 24
$269.2M
$139.5M
Q2 24
$256.7M
$147.0M
Net Profit
EXTR
EXTR
RARE
RARE
Q2 26
$10.6M
Q4 25
$7.9M
$-128.6M
Q3 25
$5.6M
$-180.4M
Q2 25
$-7.8M
$-115.0M
Q1 25
$3.5M
$-151.1M
Q4 24
$7.4M
$-133.2M
Q3 24
$-10.5M
$-133.5M
Q2 24
$-54.2M
$-131.6M
Gross Margin
EXTR
EXTR
RARE
RARE
Q2 26
61.7%
Q4 25
61.4%
Q3 25
60.6%
Q2 25
61.6%
Q1 25
61.7%
Q4 24
62.7%
Q3 24
63.0%
Q2 24
44.7%
Operating Margin
EXTR
EXTR
RARE
RARE
Q2 26
5.5%
Q4 25
4.1%
-54.7%
Q3 25
3.6%
-106.9%
Q2 25
-0.4%
-64.8%
Q1 25
3.6%
-102.6%
Q4 24
4.5%
-74.3%
Q3 24
-1.8%
-94.6%
Q2 24
-19.1%
-79.1%
Net Margin
EXTR
EXTR
RARE
RARE
Q2 26
3.3%
Q4 25
2.5%
-62.0%
Q3 25
1.8%
-112.8%
Q2 25
-2.5%
-69.0%
Q1 25
1.2%
-108.5%
Q4 24
2.6%
-80.9%
Q3 24
-3.9%
-95.7%
Q2 24
-21.1%
-89.5%
EPS (diluted)
EXTR
EXTR
RARE
RARE
Q2 26
$0.08
Q4 25
$0.06
$-1.28
Q3 25
$0.04
$-1.81
Q2 25
$-0.07
$-1.17
Q1 25
$0.03
$-1.57
Q4 24
$0.06
$-1.34
Q3 24
$-0.08
$-1.40
Q2 24
$-0.40
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXTR
EXTR
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$210.1M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-80.0M
Total Assets
$1.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXTR
EXTR
RARE
RARE
Q2 26
$210.1M
Q4 25
$219.8M
$421.0M
Q3 25
$209.0M
$202.5M
Q2 25
$231.7M
$176.3M
Q1 25
$185.5M
$127.1M
Q4 24
$170.3M
$174.0M
Q3 24
$159.5M
$150.6M
Q2 24
$156.7M
$480.7M
Total Debt
EXTR
EXTR
RARE
RARE
Q2 26
Q4 25
Q3 25
Q2 25
$180.0M
Q1 25
Q4 24
Q3 24
Q2 24
$190.0M
Stockholders' Equity
EXTR
EXTR
RARE
RARE
Q2 26
Q4 25
$95.9M
$-80.0M
Q3 25
$68.6M
$9.2M
Q2 25
$65.6M
$151.3M
Q1 25
$71.7M
$144.2M
Q4 24
$51.2M
$255.0M
Q3 24
$32.7M
$346.8M
Q2 24
$25.3M
$432.4M
Total Assets
EXTR
EXTR
RARE
RARE
Q2 26
$1.2B
Q4 25
$1.2B
$1.5B
Q3 25
$1.2B
$1.2B
Q2 25
$1.2B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.1B
$1.5B
Q3 24
$1.1B
$1.5B
Q2 24
$1.0B
$1.6B
Debt / Equity
EXTR
EXTR
RARE
RARE
Q2 26
Q4 25
Q3 25
Q2 25
2.74×
Q1 25
Q4 24
Q3 24
Q2 24
7.52×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXTR
EXTR
RARE
RARE
Operating Cash FlowLast quarter
$50.3M
$-99.8M
Free Cash FlowOCF − Capex
$7.8M
$-100.8M
FCF MarginFCF / Revenue
2.5%
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
4.75×
TTM Free Cash FlowTrailing 4 quarters
$105.3M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXTR
EXTR
RARE
RARE
Q2 26
$50.3M
Q4 25
$50.1M
$-99.8M
Q3 25
$-14.0M
$-91.4M
Q2 25
$81.9M
$-108.3M
Q1 25
$30.0M
$-166.5M
Q4 24
$21.5M
$-79.3M
Q3 24
$18.6M
$-67.0M
Q2 24
$15.5M
$-77.0M
Free Cash Flow
EXTR
EXTR
RARE
RARE
Q2 26
$7.8M
Q4 25
$43.0M
$-100.8M
Q3 25
$-20.9M
$-92.7M
Q2 25
$75.3M
$-110.7M
Q1 25
$24.2M
$-167.8M
Q4 24
$16.1M
$-79.5M
Q3 24
$11.7M
$-68.6M
Q2 24
$11.0M
$-79.0M
FCF Margin
EXTR
EXTR
RARE
RARE
Q2 26
2.5%
Q4 25
13.5%
-48.6%
Q3 25
-6.7%
-58.0%
Q2 25
24.5%
-66.5%
Q1 25
8.5%
-120.5%
Q4 24
5.8%
-48.3%
Q3 24
4.3%
-49.2%
Q2 24
4.3%
-53.7%
Capex Intensity
EXTR
EXTR
RARE
RARE
Q2 26
Q4 25
2.2%
0.5%
Q3 25
2.2%
0.8%
Q2 25
2.2%
1.5%
Q1 25
2.0%
1.0%
Q4 24
1.9%
0.1%
Q3 24
2.6%
1.2%
Q2 24
1.7%
1.4%
Cash Conversion
EXTR
EXTR
RARE
RARE
Q2 26
4.75×
Q4 25
6.37×
Q3 25
-2.49×
Q2 25
Q1 25
8.67×
Q4 24
2.92×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXTR
EXTR

Product$199.4M63%
Subscription and support$117.5M37%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons